49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/0c/e4/6b/0ce46b91-3d22-279b-52fe-d3b1a2a47107/mza_11625791986367831883.jpg/600x600bb.jpg

TMO EPM / Hemato H9J

64 episodes

4 days ago

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Medicine

Health & Fitness

RSS

All content for TMO EPM / Hemato H9J is the property of TMO EPM / Hemato H9J and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38086306/38086306-1742244045154-1956b5255857b.jpg

49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

TMO EPM / Hemato H9J

35 minutes

7 months ago

49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Discussão do artigo: "Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation" de Kumar A Blood 2025

Apresentado por: Dr. Lucas Salviano

Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Vinicius Molla